Inspire Investing LLC Lowers Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Inspire Investing LLC lessened its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 63.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,491 shares of the biotechnology company’s stock after selling 41,176 shares during the quarter. Inspire Investing LLC’s holdings in ADMA Biologics were worth $403,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC raised its holdings in ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after purchasing an additional 137,989 shares during the period. Perpetual Ltd purchased a new position in ADMA Biologics during the fourth quarter worth approximately $62,300,000. Assenagon Asset Management S.A. boosted its position in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics in the third quarter valued at approximately $61,858,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $16.08 on Friday. The company has a fifty day simple moving average of $18.56 and a 200-day simple moving average of $17.46. The firm has a market capitalization of $3.80 billion, a price-to-earnings ratio of 57.43 and a beta of 0.76. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52-week low of $5.02 and a 52-week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the prior year, the company earned $0.01 EPS. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ADMA. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.